NAD Sees Health Claims Without Clinical Trials As Risky But Possible
This article was originally published in The Rose Sheet
Executive Summary
The National Advertising Division intends its standards and reviews to be flexible but acknowledges it is “risky” for advertisers to support health claims without clinical trial RCT data, says senior attorney Kat Dunnigan.
You may also be interested in...
Breast Discomfort Supplement Claims Were Poor Fit With Study Findings
BioPharmX can support claims its Violet Iodine breast discomfort supplement is designed for women with fibrocystic breast condition, as supported by study data, but must modify claims not specific to the conditions of the women in the study, including those with premenstrual breast discomfort.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.